Your Cheddar celebrates International Women's Day on March 8th with a show dedicated to women empowerment in the boardroom.
But first, another White House shake-up. President Trump's top economic advisory Gary Cohn said Tuesday that he would be leaving the White House in the coming weeks. His departure comes on the heels of the President's announcement that he would impose tariffs on steel and aluminum imports. Chad Morganlander, Portfolio Manager at Washington Crossing Advisors joins Your Cheddar to give his predictions on the market amidst the White House departure.
Plus, Subha Barry, Senior VP and Managing Director of Working Mother Media joins to discuss the top companies for women executives based off a survey done by The National Association for Female Executives.
And Ally's Chief Financial Officer Jenn LaClair, President of Consumer & Commercial Banking Products Di Morais, and General Auditor Stephanie Richard join Kristen Scholer for a roundtable discussion on why women leadership and diversity in the workplace is so important.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
